John Glenn - 07 Dec 2025 Form 4 Insider Report for IRADIMED CORP (IRMD)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: IRMD
Reported as of: 07 Dec 2025
Net transaction value: -$1,101,740
SEC form: 4
Accepted by SEC: 10 Dec 2025, 17:00:09 UTC
Prior SEC filing: 12 Nov 2025
Next SEC filing: 12 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ John Glenn

Key filing fact

John Glenn filed Form 4 for IRADIMED CORP (IRMD) on 10 Dec 2025.

Key facts

This page summarizes John Glenn's Form 4 filing for IRADIMED CORP (IRMD).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Dec 2025, 17:00.

Change

Previous filing in this sequence was filed on 12 Nov 2025.
Current net transaction value: -$1,101,740.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001253497 Primary reporting owner

GLENN JOHN

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO
Signature: /s/ John Glenn
Signature date: 10 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,504
Change %: +420%
Price
Shares after: 13,004
Date: 07 Dec 2025
Ownership: Direct
Footnotes: F1

IRMD transaction

Common Stock

Tax liability

Transaction value: $319,930
Shares: -3,383
Change %: -26%
Price: $94.57
Shares after: 9,621
Date: 07 Dec 2025
Ownership: Direct

IRMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +21,008
Change %: +218%
Price
Shares after: 30,629
Date: 07 Dec 2025
Ownership: Direct
Footnotes: F2

IRMD transaction

Common Stock

Tax liability

Transaction value: $781,810
Shares: -8,267
Change %: -27%
Price: $94.57
Shares after: 22,362
Date: 07 Dec 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRMD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -10,504
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,504
Exercise price
Footnotes: F1, F3

IRMD transaction Derivative

Performance-based Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -21,008
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,008
Exercise price
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

Footnote F3

The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Footnote F4

On December 7, 2022, the reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2022 through December 7, 2025.